• Sales revenue increased 2% in constant currency to $2.3 billion
• Achieved underlying net profit of $322 million
• Strategic priorities advanced with the launch of the Cochlear Nucleus Nexa System
• FY27 outlook includes low single-digit constant currency sales revenue growth
• Expected underlying net profit of $330-350 million for FY27

Cochlear Ltd announced its FY26 results, with sales revenue increasing by 2% in constant currency to $2.3 billion, and underlying net profit reaching $322 million. The company met its revised guidance provided in April. Key highlights include the strategic advancement with the launch of the Cochlear Nucleus Nexa System, which aims to improve patient experience, and increased investment in R&D. The company is taking action to support growth, such as reducing fixed costs to invest in growth and margin, accelerating the medicalization of hearing loss, and building on the Nexa platform. For FY27, Cochlear expects low single-digit constant currency sales revenue growth and underlying net profit of $330-350 million. The outlook includes modest revenue growth in developed markets, modest growth in emerging markets, and expected gross margin of 70-71%.

FY27 expected underlying net profit of $330-350 million

For FY27, Cochlear expects low single-digit constant currency sales revenue growth and underlying net profit of $330-350 million. The outlook includes modest revenue growth in developed markets and modest growth in emerging markets. Gross margin is expected to be 70-71%.